欧州連合 - スウェーデン語 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiska medel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - aztreonam - pulver till injektions-/infusionsvätska, lösning - aztreonam 1 g aktiv substans - aztreonam

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - didanosin - enterokapsel, hård - 125 mg - didanosin 125 mg aktiv substans; natriumlaurilsulfat hjälpämne - didanosin

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - didanosin - enterokapsel, hård - 200 mg - didanosin 200 mg aktiv substans; natriumlaurilsulfat hjälpämne - didanosin

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - didanosin - enterokapsel, hård - 250 mg - didanosin 250 mg aktiv substans; propylenglykol hjälpämne; natriumlaurilsulfat hjälpämne - didanosin

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - didanosin - enterokapsel, hård - 400 mg - natriumlaurilsulfat hjälpämne; didanosin 400 mg aktiv substans; propylenglykol hjälpämne - didanosin

欧州連合 - スウェーデン語 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastiska medel - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 och 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - nystatin - oral suspension - 100000 iu/ml - nystatin 100000 ie aktiv substans; metylparahydroxibensoat hjälpämne; xylitol hjälpämne - nystatin

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - triamcinolonacetonid - injektionsvätska, suspension - 10 mg/ml - triamcinolonacetonid 10 mg aktiv substans; bensylalkohol hjälpämne - triamcinolon

スウェーデン - スウェーデン語 - Läkemedelsverket (Medical Products Agency)

bristol-myers squibb ab - triamcinolonacetonid - injektionsvätska, suspension - 40 mg/ml - triamcinolonacetonid 40 mg aktiv substans; bensylalkohol hjälpämne - triamcinolon